-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Mereo BioPharma Group, Lowers Price Target to $3

Benzinga·01/13/2026 11:56:44
Listen to the news
Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers the price target from $5 to $3.